Trial Search Results

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

This clinical trial is looking at brain function in young patients receiving methotrexate for acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain function may help doctors plan cancer treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)


  • Procedure: Cognitive Assessment
  • Procedure: Diffusion Tensor Imaging
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Procedure: Psychosocial Assessment and Care


Inclusion Criteria:

   - Diagnosis of acute lymphoblastic leukemia

   - Enrolled on COG-AALL0434 (Cohort #1 only) or COG-AALL0232 (Cohorts #1 and #2)

      - Patients must have received either high-dose methotrexate or escalating-dose
      methotrexate during interim maintenance.

   - No CNS-3 disease

   - Patients must enroll within 8-24 months after completion of therapy on COG-AALL0232
   and no evidence of relapsed or secondary malignancy

   - No known significant neurodevelopmental disability unrelated to cancer diagnosis
   including, but not limited to, any of the following:

      - Down syndrome

      - Fragile X mental retardation

      - Autism

      - Pervasive developmental disability

      - Seizure disorder

   - Attention-deficit hyperactivity disorder or specific learning disability (e.g.,
   dyslexia) allowed

   - No sensory impairment (e.g., pre-existing uncorrectable vision impairment or deafness)

   - No cranial radiation therapy

Ages Eligible for Study

1 Year - 17 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pediatric Hematology/Oncology
Not Recruiting